Skip to main content
Premium Trial:

Request an Annual Quote

Lexicon Genetics Lands Merck as Licensee

NEW YORK, Aug. 15 – Merck has acquired a non-exclusive license to Lexicon Genetics' gene-targeting technologies, bringing to 16 the total number of licensees for the technologies, Lexicon said on Wednesday.

Details of the agreement were not disclosed.

Lexicon Genetics, of The Woodlands, Texas, uses gene-knockout technology to identify genes of medical interest. In addition to licensing this technology, Lexicon uses it to develop its own drug-discovery efforts.

Lexicon also sells subscriptions to its LexVision database of mouse gene-knockout data, which includes physiological data such as measurements of whole blood-cell count, X-rays, MRI and CT scans, and certain neurological tests. 

Last week, Lexicon announced that GlaxoSmithKline agreed to a multi-year, non-exclusive sublicense to Lexicon Genetics' gene targeting technologies. Under the terms of the agreement, GlaxoSmithKline will pay an undisclosed one-time fee. 

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.